End-To-End Manufacturing Of Autologous CAR T Cell Therapies With The Sefia™ Cell Therapy Manufacturing Platform

By Cindy Farino Reyes, Rubayat Jamal, Mack Ryan, Nick McKenzie, Craig Mizzoni, Srinidhi Deshpande, Yanling Liu, Anna Maystrenko, Dana Arab, Céline Bertaux, Melissa Maggioni, Panteleimon Zotos, Federico Zanoni, Mojtaba Parvizi, Marine De Lageneste, and Federico Franchi

Gene-modified T-cell therapies have demonstrated clinical efficacy in targeting cancer and hold promise for treating other diseases. Despite these advances, commercializing these innovative therapies remains challenging due to their complexity and high manufacturing costs. To address these issues and provide scalable, cost-effective solutions, the Sefia™ cell therapy manufacturing platform has been developed. This modular, functionally closed technology includes the Sefia Select™ system for automating T cell magnetic isolation, washing, and final formulation, as well as the Sefia expansion system for automating the activation, transduction, and expansion of chimeric antigen receptor (CAR) T cells. Continue reading to learn more about this end-to-end solution for the manufacture of autologous CAR T cell therapies.